Bone Marrow Mesenchymal Stem Cells in Acute-on-Chronic Liver Failure Grades 2 and 3: A Phase I-II Randomized Clinical Trial

Figure 3

Variations regarding Child–Pugh, MELD and ACLF scores before and after the infusion of 5 doses of the intervention group ((a); n = 1) and in the placebo group after 90 days ((b); n = 2). MELD, Model for end-stage liver disease; ACLF, acute-on-chronic liver failure.

(a)

(b)